Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
| Autor: | Roberto Bajetta, Sara De Dosso, Elena Verzoni, Laura Catena, Giuseppe Procopio, Leonardo Ferrari, Emilio Bajetta, Antonia Martinetti, Ettore Bichisao, Barbara Formisano, Marco Platania |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Adult
Male Antimetabolites Antineoplastic Cancer Research medicine.medical_specialty XELOX Regimen Organoplatinum Compounds Oxaloacetates medicine.medical_treatment Antineoplastic Agents macromolecular substances Toxicology Deoxycytidine Gastroenterology Capecitabine Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Humans Medicine Pharmacology (medical) Survival analysis Aged Aged 80 and over Pharmacology Chemotherapy business.industry Primary sites Middle Aged Survival Analysis Oxaliplatin Surgery carbohydrates (lipids) Drug Combinations Neuroendocrine Tumors stomatognathic diseases medicine.anatomical_structure Somatostatin Oncology Disease Progression Chromogranin A Female Fluorouracil business Pancreas medicine.drug |
| Zdroj: | Cancer Chemotherapy and Pharmacology. 59:637-642 |
| ISSN: | 1432-0843 0344-5704 |
| Popis: | The aim of this trial was to evaluate the safety and efficacy of oxaliplatin and capecitabine (XELOX) in neuroendocrine tumours’ (NETs) treatment. Forty patients (pts) with advanced NETs were treated. Of these, 13 had untreated poorly differentiated NETs, 27 had well-differentiated NETs in progression after somatostatin analogues. Patients received oxaliplatin e.v. 130 mg/mq i.v. and capecitabine 2,000 mg/mq/die. The primary sites of the disease were: lung (10 pts), pancreas (15 pts), small bowel (8 pts), unknown (1 pt), others (6 pts). In 13 pts with poorly differentiated NETs objective responses (OR) were: 3 PR (23%), 1 SD (7%), 9 PD (70%). Biochemical responses were 11%. In 27 patients with well-differentiated NETs the OR were: 8 PR (30%), 13 SD (48%) and 6 PD (22%). Biochemical and symptomatic responses were 20 and 50%, respectively. The XELOX regimen is effective and tolerated in well-differentiated NETs after progression following somatostatin analogues. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink